Dimensional Fund Advisors LP Has $10.55 Million Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Dimensional Fund Advisors LP grew its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 67.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,104,058 shares of the biopharmaceutical company's stock after purchasing an additional 444,790 shares during the period. Dimensional Fund Advisors LP owned approximately 2.04% of Emergent BioSolutions worth $10,554,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of EBS. Covestor Ltd increased its stake in Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 2,893 shares during the period. LPL Financial LLC increased its stake in Emergent BioSolutions by 34.5% during the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 3,875 shares in the last quarter. Federated Hermes Inc. boosted its stake in Emergent BioSolutions by 2.2% during the 4th quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company's stock valued at $2,656,000 after purchasing an additional 6,058 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Emergent BioSolutions during the 4th quarter valued at about $63,000. Finally, Landscape Capital Management L.L.C. lifted its holdings in Emergent BioSolutions by 39.5% in the fourth quarter. Landscape Capital Management L.L.C. now owns 23,595 shares of the biopharmaceutical company's stock valued at $226,000 after acquiring an additional 6,682 shares during the period. Institutional investors own 78.40% of the company's stock.

Analysts Set New Price Targets

EBS has been the subject of several recent research reports. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, April 1st.

Insider Buying and Selling at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares of the company's stock, valued at $589,413. The trade was a 25.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by insiders.

Emergent BioSolutions Trading Down 3.4%

NYSE:EBS traded down $0.19 during trading hours on Thursday, reaching $5.45. 294,683 shares of the stock were exchanged, compared to its average volume of 1,871,899. Emergent BioSolutions Inc. has a twelve month low of $4.02 and a twelve month high of $15.10. The company has a market capitalization of $296.14 million, a price-to-earnings ratio of -1.32 and a beta of 2.09. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The business has a 50-day moving average of $5.14 and a two-hundred day moving average of $7.86.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating analysts' consensus estimates of $0.49 by $0.22. The business had revenue of $222.20 million during the quarter, compared to analysts' expectations of $218.50 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. On average, equities analysts predict that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions announced that its Board of Directors has authorized a share repurchase plan on Monday, March 31st that authorizes the company to buyback $50.00 million in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to purchase up to 19% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.